Andreas Nuessler, Head, Eberhard-Karls University, Tübingen
Abstract
There is increasing evidence that mesenchymal stem cells can differentiate into hepatocyte-like cells. However many open questions remain in order to use these cells routinously in drug development. The present paper will present advantages and disadvantages using MSCs in drug development.